Consideration Needed for early Anticoagulation Following Intravenous tPA in Patients with COVID-19

J Stroke Cerebrovasc Dis. 2021 Jul;30(7):105769. doi: 10.1016/j.jstrokecerebrovasdis.2021.105769. Epub 2021 Apr 2.

Authors

Angelo Jimenez¹, Arvind Ravinutala¹, Jonathan Eskenazi², Prissilla Xu³, Antonio Liu⁴

Affiliations

¹ Neurology, Adventist Health White Memorial, Los Angeles, CA USA.
² Neurology, California Hospital Medical Center, Los Angeles, CA USA.
³ Pharmacy Services, Adventist Health White Memorial, Los Angeles, CA USA.
⁴ Neurology, Adventist Health White Memorial, Los Angeles, CA USA; Neurology, California Hospital Medical Center, Los Angeles, CA USA. Electronic address: [email protected].

PMID: 33863617
PMCID: PMC8017529
DOI: 10.1016/j.jstrokecerebrovasdis.2021.105769

No abstract available

Publication types

Letter
Comment

MeSH terms

Anticoagulants / adverse effects
Brain Ischemia* / drug therapy
COVID-19*
Fibrinolytic Agents / adverse effects
Humans
Ischemic Stroke*
SARS-CoV-2
Stroke* / diagnosis
Stroke* / drug therapy
Tissue Plasminogen Activator / adverse effects

Substances

Anticoagulants
Fibrinolytic Agents
Tissue Plasminogen Activator